Guangdong Zhongsheng Ruichuang Biotechnology

Zonsen Ruichuang is a China-based biopharmaceutical company focused on the development of innovative drugs for infectious diseases and non-alcoholic steatohepatitis (NASH). A subsidiary of Guangdong Zhongsheng Pharmaceutical, the company has successfully brought products to market, including Leritrelvir for the treatment of COVID-19. Its pipeline features several high-potential small molecules targeting influenza and metabolic liver diseases, with a strong emphasis on addressing unmet medical needs in respiratory and digestive health. The company operates integrated R&D facilities and maintains a robust clinical pipeline ranging from pre-clinical to Phase 3 stages.